ABL1 (T315I)
Sign in to save this workspaceABL1 · Variant type: point · HGVS: p.T315I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ponatinib | 99.2% | 0.8% | 78.23 |
| 2 | Axitinib | 98.8% | 1.2% | 93.23 |
| 3 | Crizotinib | 96.2% | 3.8% | 91.39 |
| 4 | Brigatinib | 94.8% | 5.2% | 82.96 |
| 5 | Bosutinib | 94.8% | 5.2% | 87.22 |
| 6 | Vandetanib | 93.8% | 6.2% | 95.74 |
| 7 | Nintedanib | 92.3% | 7.8% | 90.23 |
| 8 | Selpercatinib | 89.2% | 10.8% | 96.72 |
| 9 | Pacritinib | 88.5% | 11.5% | 88.64 |
| 10 | Entrectinib | 85.4% | 14.6% | 93.69 |
| 11 | Canertinib | 83.9% | 16.1% | 96.49 |
| 12 | Sunitinib | 82.5% | 17.5% | 91.73 |
| 13 | Repotrectinib | 79.8% | 20.2% | 84.21 |
| 14 | Gilteritinib | 78.7% | 21.3% | 88.97 |
| 15 | Defactinib | 77.6% | 22.4% | 92.68 |
| 16 | Pralsetinib | 77.2% | 22.8% | 93.43 |
| 17 | Fedratinib | 77.0% | 23.0% | 96.21 |
| 18 | Tivozanib | 67.9% | 32.1% | 92.42 |
| 19 | Dacomitinib | 63.0% | 37.0% | 97.99 |
| 20 | Erlotinib | 55.9% | 44.1% | 99.75 |
| 21 | Dasatinib | 50.1% | 49.9% | 87.97 |
| 22 | Deucravacitinib | 43.9% | 56.1% | 98.99 |
| 23 | Abemaciclib | 42.5% | 57.5% | 91.48 |
| 24 | Erdafitinib | 40.7% | 59.3% | 95.71 |
| 25 | Pexidartinib | 33.9% | 66.1% | 99.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ponatinib | 99.2% | 100.0% | -0.8% |
| Axitinib | 98.8% | 99.4% | -0.6% |
| Crizotinib | 96.2% | 97.0% | -0.8% |
| Brigatinib | 94.8% | 82.8% | +12.0% |
| Bosutinib | 94.8% | 99.7% | -4.9% |
| Vandetanib | 93.8% | 95.7% | -1.9% |
| Nintedanib | 92.3% | 99.9% | -7.6% |
| Selpercatinib | 89.2% | — | — |
| Pacritinib | 88.5% | 92.0% | -3.5% |
| Entrectinib | 85.4% | — | — |
| Canertinib | 83.9% | 91.6% | -7.7% |
| Sunitinib | 82.5% | — | — |
| Repotrectinib | 79.8% | 93.6% | -13.8% |
| Gilteritinib | 78.7% | — | — |
| Defactinib | 77.6% | — | — |
| Pralsetinib | 77.2% | — | — |
| Fedratinib | 77.0% | 82.7% | -5.6% |
| Tivozanib | 67.9% | 95.8% | -27.9% |
| Dacomitinib | 63.0% | 80.8% | -17.8% |
| Erlotinib | 55.9% | — | — |
| Dasatinib | 50.1% | 98.6% | -48.5% |
| Deucravacitinib | 43.9% | — | — |
| Abemaciclib | 42.5% | — | — |
| Erdafitinib | 40.7% | 90.9% | -50.3% |
| Pexidartinib | 33.9% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| haematopoietic_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| malignant_melanoma_skin | Skin | ref |
| adnexal_tumour_skin | Skin | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 24.0ms